{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"324"}]}],"title":"Hemoglobin (anemia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"91"}]}],"title":"Hemoglobin (anemia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"128"}]}],"title":"Hemoglobin (anemia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"98"}]}],"title":"Hemoglobin (anemia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}],"title":"Hemoglobin (anemia), Increase to G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"300"}]}],"title":"Lym. (lymphocytopenia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"26"}]}],"title":"Lym. (lymphocytopenia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"50"}]}],"title":"Lym. (lymphocytopenia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"96"}]}],"title":"Lym. (lymphocytopenia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"128"}]}],"title":"Lym. (lymphocytopenia), Increase to G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"394"}]}],"title":"Tot Neu. (neutropenia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"90"}]}],"title":"Tot Neu. (neutropenia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"104"}]}],"title":"Tot Neu. (neutropenia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"129"}]}],"title":"Tot Neu. (neutropenia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"71"}]}],"title":"Tot Neu. (neutropenia), Increase to G4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"376"}]}],"title":"WBC (leukocytopenia), Any Grade Increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"94"}]}],"title":"WBC (leukocytopenia), Increase to G1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"142"}]}],"title":"WBC (leukocytopenia), Increase to G2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"117"}]}],"title":"WBC (leukocytopenia), Increase to G3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"23"}]}],"title":"WBC (leukocytopenia), Increase to G4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"449"}],"units":"Participants"}],"description":"Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.","groups":[{"description":"Participants completing the OL Phase were administered matching placebo tablets QD in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG000","title":"Placebo+Antiviral Therapy: DB Phase"},{"description":"Participants completing the OL Phase continued on the same dose of eltrombopag received in the OL Phase (dose that effectively raised platelets to \\>=90 Gi/L) in combination with antiviral therapy (peginterferon alfa-2a and ribavirin) for a duration of either 24 or 48 weeks (for participants with Genotype 2/3) or 48 weeks (for participants with Non-Genotype 2/3).","id":"OG001","title":"Eltrombopag+Antiviral Therapy: DB Phase"}],"paramType":"NUMBER","populationDescription":"Safety DB Population","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)","title":"Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS During the DB Phase","type":"SECONDARY","unitOfMeasure":"participants"}